Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 3/20 | 0.37 |
| ▸ | MPO | P05164 | 2/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.35 |
| ▸ | FAP | Q12884 | 1/20 | 0.32 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.32 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.32 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.32 |
| ▸ | NAAA | Q02083 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17713426 | 0.88 | NAAA (0.36) | DPP4MPOSLC6A4FAPDPP8 | |
| SCHEMBL17713357 | 0.77 | TAAR1 (0.50) | SLC6A4 | |
| SCHEMBL17713301 | 0.75 | KDM1A (0.32) | — | |
| SCHEMBL17713491 | 0.75 | DPP4 (0.40) | DPP4 | |
| SCHEMBL17713492 | 0.75 | PYCR1 (0.39) | DPP4NAAA | |
| SCHEMBL31248059 | 0.75 | MPO (0.42) | DPP4MPOSLC6A4 | |
| SCHEMBL30814757 | 0.72 | TAAR1 (0.52) | DPP4MPO | |
| SCHEMBL535214 | 0.72 | TAAR1 (0.52) | DPP4MPO | |
| Hydrochloric Acid SCHEMBL18524413 | 0.71 | TAAR1 (0.50) | DPP4MPO | |
| SCHEMBL30814733 | 0.71 | CSNK2A1 (0.40) | DPP4MPOSLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9901571-B2 | Tetrahydropyrazolopyridine derivatives as ghrelin receptor agonists | RAQUALIA PHARMA INC. (JP) | 2018-02-27 | — | — | US | disclosed |
| US-20170304277-A1 | TETRAHYDROPYRAZOLOPYRIDINE DERIVATIVES AS GHRELIN RECEPTOR AGONISTS | RAQUALIA PHARMA INC. (JP) | 2017-10-26 | — | — | US | disclosed |
| EP-3212648-A1 | TETRAHYDROPYRAZOLOPYRIDINE DERIVATIVES AS GHRELIN RECEPTOR AGONISTS | RaQualia Pharma Inc. (JP) | 2017-09-06 | — | — | EP | disclosed |
| WO-2016067638-A1 | TETRAHYDROPYRAZOLOPYRIDINE DERIVATIVES AS GHRELIN RECEPTOR AGONISTS | RAQUALIA PHARMA INC. (JP) | 2016-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170304277-A1 | TETRAHYDROPYRAZOLOPYRIDINE DERIVATIVES AS GHRELIN RECEPTOR AGONISTS | GHSR, GHRHR, GIPR | DPP4 851/4885MPO 4404/4885SLC6A4 1526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.